Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC1 | P33527 | 1/20 | 0.50 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.50 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.50 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
| ▸ | PPP3CB | P16298 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | ELANE | P08246 | 8/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | RORC | P51449 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13757868 | 1.00 | ABCC1 (0.50) | ABCC1ABCC2ABCG2CTSBPPP3CB | |
| SCHEMBL3809562 | 0.95 | ABCC1 (0.49) | ABCC1ABCC2ABCG2CTSBPPP3CB | |
| SCHEMBL8131104 | 0.95 | ABCC1 (0.49) | ABCC1ABCC2ABCG2CTSBPPP3CB | |
| SCHEMBL3372948 | 0.95 | ABCC1 (0.51) | ABCC1ABCC2ABCG2CTSBPPP3CB | |
| SCHEMBL13757860 | 0.95 | ABCC1 (0.51) | ABCC1ABCC2ABCG2CTSBPPP3CB | |
| SCHEMBL3376743 | 0.91 | ABCC1 (0.49) | ABCC1ABCC2ABCG2CTSBPPP3CB | |
| SCHEMBL8145156 | 0.91 | CYP3A4 (0.42) | ABCC1ABCC2ABCG2CTSBPPP3CB | |
| SCHEMBL3370492 | 0.90 | ABCC1 (0.49) | ABCC1ABCC2ABCG2CTSBPPP3CB | |
| SCHEMBL13757897 | 0.90 | ABCC1 (0.49) | ABCC1ABCC2ABCG2CTSBPPP3CB | |
| SCHEMBL8143370 | 0.90 | ABCC1 (0.47) | ABCC1ABCC2ABCG2CTSBPPP3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8809267-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-20140051626-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-8513186-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-20090186869-A1 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186869-A1 | Antiviral compounds | MAVS, EIF2AK2, ZC3HAV1 | ABCC1 1980/4885ABCC2 2957/4885ABCG2 1209/4885 |
| US-20140051626-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | ABCC1 1980/4885ABCC2 2957/4885ABCG2 1209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.